Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
| Status: | Recruiting |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | October 2005 |
| End Date: | December 2016 |
| Contact: | Gerald A Fishman, MD |
| Email: | gerafish@uic.edu |
| Phone: | 312.996.8939 |
Seven patients with X-linked retinoschisis were treated with dorzolamide and the response to
this treatment was monitored using OCT. These patients were also tested for the causative
gene mutation and the resultant mechanism of functional loss of retinoschisin. It was
observed that a response to dorzolamide may be seen irrespective of the mechanism that leads
to decrease in function of retinoschisin.
this treatment was monitored using OCT. These patients were also tested for the causative
gene mutation and the resultant mechanism of functional loss of retinoschisin. It was
observed that a response to dorzolamide may be seen irrespective of the mechanism that leads
to decrease in function of retinoschisin.
A percentage of patients with retinal degeneration, a group of progressive blinding
diseases, are known to develop fluid within the center part of their retina known as macular
edema. Previous studies have documented that an oral form of carbonic anhydrase inhibitor
(acetazolamide) can be effective in reducing the amount of macular edema in such patients
(Archives of Ophthalmology, 106:1190-1195, 1988; 107:1445-1452, 1989). However, the use of
the oral form of this medication is known to cause clinically significant side effects such
as fatigue and loss of appetite.
A topical form of carbonic anhydrase inhibitor, (Trusopt) has promise for having a similar
beneficial effect on the retinal fluid while not having the systemic side effects observed
with the oral form of medication.
In the current study, we propose to use topical Trusopt in a group of patients with retinal
degeneration (RD) to determine its efficacy in reducing the amount of retinal fluid in
patients with RD and macular edema. The methods will involve an initial one month treatment
with topical Trusopt three times a day in each eye. After a period of one month, patients
will return for a follow-up examination. At baseline, they will have had a measurement of
their center vision and a measurement of their macular fluid with a photographic-like
procedure termed optical coherence tomography (OCT). After the one month period of
treatment, they will again have a measurement of their vision and re-evaluation with OCT. An
improvement of one line or more of vision will be considered as a significant improvement.
Since the short-term intervisit variability in the area of macular edema in patients with RD
can vary from 11% to 16%, a reduction in fluid of at least 25% in area will be considered as
a clinically significant improvement of macular edema.
diseases, are known to develop fluid within the center part of their retina known as macular
edema. Previous studies have documented that an oral form of carbonic anhydrase inhibitor
(acetazolamide) can be effective in reducing the amount of macular edema in such patients
(Archives of Ophthalmology, 106:1190-1195, 1988; 107:1445-1452, 1989). However, the use of
the oral form of this medication is known to cause clinically significant side effects such
as fatigue and loss of appetite.
A topical form of carbonic anhydrase inhibitor, (Trusopt) has promise for having a similar
beneficial effect on the retinal fluid while not having the systemic side effects observed
with the oral form of medication.
In the current study, we propose to use topical Trusopt in a group of patients with retinal
degeneration (RD) to determine its efficacy in reducing the amount of retinal fluid in
patients with RD and macular edema. The methods will involve an initial one month treatment
with topical Trusopt three times a day in each eye. After a period of one month, patients
will return for a follow-up examination. At baseline, they will have had a measurement of
their center vision and a measurement of their macular fluid with a photographic-like
procedure termed optical coherence tomography (OCT). After the one month period of
treatment, they will again have a measurement of their vision and re-evaluation with OCT. An
improvement of one line or more of vision will be considered as a significant improvement.
Since the short-term intervisit variability in the area of macular edema in patients with RD
can vary from 11% to 16%, a reduction in fluid of at least 25% in area will be considered as
a clinically significant improvement of macular edema.
Inclusion Criteria:
- Presence of cystic lesions on OCT testing
Exclusion Criteria:
- Allergic reaction to sulpha containing compounds
- Intolerance to dorzolamide
We found this trial at
1
site
Click here to add this to my saved trials
